Unproven stem cell treatment industry in the USA: a concerning boom – BioNews
Affimed Announces 100% Objective Response Rate at Highest Dose in Phase 1-2 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate…
22 November 2021 In the USA, clinics offering stem cell therapies not approved by the USFood and Drug Administration (FDA) expanded four-fold in just five years. These putative medical treatments lack concrete evidence of safety and efficacy, a study published in the journal Cell Stem Cell earlier this year has shown.
Leukaemia: how can stem cells help? | Eurostemcell
HEIDELBERG, Germany, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Affimed N.V
Induced Pluripotent Stem Cells and Their Potential for …
Like most cancers, leukaemias are caused by a series of rare mutations (changes) in certain genes. These generally arise spontaneously at a very low rate inside primitive blood cell precursors throughout life.
In an Astonishing Feat, a New Drug Reversed Paralysis in Mice With Spinal Cord Injury – ScienceAlert
Curr Cardiol Rev. 2013 Feb; 9(1): 6372
CELULARITY INC Management’s Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) – marketscreener.com
US scientists have developed a new form of drug that promotes the regeneration of cells and reversed paralysis in mice with spinal injuries, allowing them to walk again within four weeks of treatment. The research was published in the journal Science on Thursday, and the team of Northwestern University scientists behind it hope to approach the Food and Drug Administration (FDA) as early as next year to propose human trials
High Induction of IL-6 Secretion From hUCMSCs Optimize the Potential of hUCMSCs and TCZ as Therapy for COVID-19-Related ARDS – DocWire News
The following discussion and analysis should be read in conjunction with ourfinancial statements and accompanying notes included herein and the financialstatements and accompanying notes thereto for the fiscal year ended December 31,2020 and the related Management's Discussion and Analysis of Financial Conditionand Results of Operations, which are contained in the prospectus, dated August12, 2021 (the "Prospectus") filed by Celularity Inc.
PRESS RELEASE : Vita 34 again increases sales and margins in the third quarter – marketscreener.com
This article was originally published here Cell Transplant. 2021 Jan-Dec;30:9636897211054481. doi: 10.1177/09636897211054481.
Hiltzik: The battle against unlicensed stem cell clinics – Los Angeles Times
DGAP-News: Vita 34 AG / Key word(s): Quarter Results Vita 34 again increases sales and margins in the third quarter 2021-11-11 / 07:30 The issuer is solely responsible for the content of this announcement. ----------------------------------------------------------------------------------------------------------------------- Vita 34 again increases sales and margins in the third quarter
Cord blood cell transplantation and curcumin administration tested as therapy of Tay-Sachs disease – EurekAlert
In 2017, the Food and Drug Administration closed a loophole exploited by clinics pitching unproven, ineffective and potentially hazardous stem cell therapies directly to consumers. Those treatments were illegal, the FDA ruled.
image:(a) Dynamic changes in the HexA activity in the TSD patients plasma after UCBCT and curcumin administration; normal level of HexA activity observed in healthy donors is 24148 nmol/mL/h; (b) Dynamic changes in the HexA concentration in the TSD patients serum after UCBCT and curcumin administration. The HexA concentration range measured in a cohort of healthy donors (n = 10) is shown in gray; (c) Dynamic changes in the GM2 level in the TSD patients plasma after UCBCT and curcumin administration.